Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression

被引:0
作者
J Du
X Liang
Y Liu
Z Qu
L Gao
L Han
S Liu
M Cui
Y Shi
Z Zhang
L Yu
L Cao
C Ma
L Zhang
Y Chen
W Sun
机构
[1] School of Medicine,Department of Immunology
[2] Shandong University,Department of Pathophysiology
[3] Central Laboratory of General Surgery,Department of Physiology
[4] Shandong Qianfoshan Hospital,Department of Pathology and Laboratory Medicine
[5] Shandong University,undefined
[6] Shandong University,undefined
[7] Hospital of Infectious Diseases,undefined
[8] University of Pennsylvania,undefined
来源
Cell Death & Differentiation | 2009年 / 16卷
关键词
Hepatitis B Virus; HBc; TRAIL; apoptosis; DR5;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatitis B virus (HBV) causes chronic hepatitis in hundreds of millions of people worldwide, which can eventually lead to hepatocellular carcinoma (HCC). The molecular mechanisms underlying HBV persistence are not well understood. TRAIL, the TNF-related apoptosis-inducing ligand, has recently been implicated in hepatocyte death during HBV infection. We report here that the HBV core protein (HBc) is a potent inhibitor of TRAIL-induced apoptosis. Overexpressing HBc significantly decreased TRAIL-induced apoptosis of human hepatoma cells, whereas knocking-down HBc expression in hepatoma cells transfected with HBV genome enhanced it. When present in the same cell, HBc blocked the pro-apoptotic effect of the HBV X protein (HBx). The resistance of HBc-expressing cells to TRAIL-induced apoptosis was associated with a significant reduction in death receptor 5 (DR5) expression. Upon transfection, HBc significantly repressed the promoter activity of the human DR5 gene. Importantly, HBc gene transfer inhibited hepatocyte death in a mouse model of HBV-induced hepatitis; and in patients with chronic hepatitis, DR5 expression in the liver was significantly reduced. These results indicate that HBc may prevent hepatocytes from TRAIL-induced apoptosis by blocking DR5 expression, which in turn contributes to the development of chronic hepatitis and HCC. They also call into question the potential side effects of HBc-based vaccines.
引用
收藏
页码:219 / 229
页数:10
相关论文
共 189 条
[1]  
Beasley RP(1981)A prospective study of 22 707 men in Taiwan Hepatocellular carcinoma and hepatitis B virus Lancet 2 1129-1133
[2]  
Hwang LY(2001)A new hypothesis of pathogenetic mechanism of viral hepatitis B and C Med Hypotheses 56 405-408
[3]  
Lin CC(1995)Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673-682
[4]  
Chien CS(1997)An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 815-818
[5]  
Liu DX(2007)Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax J Immunol 178 503-510
[6]  
Wiley SR(2007)Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model Biochem Biophys Res Commun 352 329-334
[7]  
Schooley K(2007)The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2 Apoptosis 12 1827-1836
[8]  
Smolak PJ(1998)TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling FEBS Lett 424 41-45
[9]  
Din WS(1997)Characterization of two receptors for TRAIL FEBS Lett 416 329-334
[10]  
Huang CP(1999)Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor Cancer Res 59 2770-2775